RxDoctor Payments Data

Nivas Balasubramaniyam, MD

Interventional Cardiology · Lafayette, INNPI 1306179643

Payments from drug & device makers

$9,618in general payments, 2019–2025

Across 96 payments — averaging $100.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Edwards Lifesciences$3K
  • Abbott$468
  • Medtronic$459
  • Baylis Medical Company Inc$351
  • Abiomed$190
  • plus $414 from 9 others

What the payments were for

  • Travel & lodging$5,80960%
  • Food & beverage$3,80840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,618 in reported general payments places this provider in the 55th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$122,812
Medicare patients
816
Services billed
1,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$208,593
XareltoRivaroxaban44$65,032
EntrestoSacubitril/Valsartan23$27,837
Repatha SureclickEvolocumab22$14,410
BrilintaTicagrelor14$8,937
Atorvastatin Calcium291$2,879
Metoprolol Succinate250$2,463
ClopidogrelClopidogrel Bisulfate204$2,228
Digoxin37$2,199
Ezetimibe31$2,006
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$907
Amlodipine Besylate151$822
Losartan Potassium82$760
Flecainide Acetate24$693
Carvedilol82$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$208,593156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →